Effects of inhaled JAK inhibitor GDC-4379 on exhaled nitric oxide and peripheral biomarkers of inflammation
Hubert Chen, Irene Braithwaite(Medical Research Institute of New Zealand), Jenny Sparks(Wellington Hospital), Mark S. Wilson(Gene Therapy Laboratory), Marjan Doppen(Medical Research Institute of New Zealand), Michele A. Grimbaldeston(Acentech (United States)), Richard Beasley(Medical Research Institute of New Zealand), Joshua Galanter, Maria E. Wilson(Genesys (United States)), Karen Oldfield(Wellington Hospital), Tracy Staton, Matthew R. Durk(University of Illinois Urbana-Champaign), Stacey Kung(Wellington Hospital), Avi Eliahu(Genesys (United States)), Melissa H. Black(Wellington Hospital), Hallam Gugelmann(University of Guam), David F. Choy, Rui Zhu(Chinese Academy of Medical Sciences & Peking Union Medical College), Yixuan Zou(Genesys (United States)), Ryan Owen(Genesys (United States)), Rebecca Kunder(Genesys (United States)), Joanna K. Chang(Center for Health and Gender Equity)
Cited by 13
Related Papers
Type 2 immunity in tissue repair and fibrosis
|Nature reviews. Immunology|2017|1.1k
Pulmonary fibrosis: pathogenesis, etiology and regulation
|Mucosal Immunology|2009|834
Arginase-1–Expressing Macrophages Suppress Th2 Cytokine–Driven Inflammation and Fibrosis
|PLoS Pathogens|2009|808
Bleomycin and IL-1β–mediated pulmonary fibrosis is IL-17A dependent
|The Journal of Experimental Medicine|2010|740